Similarly, in prostate cancer, we demonstrated that MCs can promote the growth of adenocarcinoma by supplying MMP9 [42] and suppressing the anti-tumor T cell response [43]; however, at the same time, they protect against aggressive neuroendocrine variants [42,44] that can emerge de novo or in resistance to hormone therapy. The gene discussed is MMP9; the disease is adenocarcinoma.